{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:36:34Z","timestamp":1784543794505,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejrad.2021.110107","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T01:59:13Z","timestamp":1639360753000},"page":"110107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy"],"prefix":"10.1016","volume":"146","author":[{"given":"Gregor","family":"Schweighofer-Zwink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhaneh","family":"Manafi-Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00f6lblinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hehenwarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Harsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2021.110107_b0005","doi-asserted-by":"crossref","unstructured":"W.-Q.L. Natalie H. Matthews, Abrar A. Qureshi, Martin A. Weinstock, Eunyoung Cho, Epidemiology of Melanoma, in: W.H. Ward, J.M. Farma, Cutaneous Melanoma: Etiology and Therapy [Internet], Codon, Brisbane, Australia, 2017, pp. 3-22. https:\/\/doi.org\/10.15586\/codon.cutaneousmelanoma.2017.ch1.","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1"},{"issue":"12","key":"10.1016\/j.ejrad.2021.110107_b0010","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejrad.2021.110107_b0015","doi-asserted-by":"crossref","unstructured":"M.C.T. van Zeijl, L.C. de Wreede, A.J.M. van den Eertwegh, M. Wouters, A. Jochems, M.G. Schouwenburg, M.J.B. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. Ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, J.J.M. van der Hoeven, J. Haanen, Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry, Eur. J. Cancer. 144 (2021) 242-251. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.028.","DOI":"10.1016\/j.ejca.2020.11.028"},{"key":"10.1016\/j.ejrad.2021.110107_b0020","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"van Zeijl","year":"2020","journal-title":"Int. J. Cancer."},{"issue":"S1","key":"10.1016\/j.ejrad.2021.110107_b0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","article-title":"The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy","volume":"44","author":"Wong","year":"2017","journal-title":"Euro. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2021.110107_b0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2015.11.011","article-title":"Metastatic melanoma treatment: Combining old and new therapies","volume":"98","author":"Davey","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.ejrad.2021.110107_b0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin. Cancer. Res."},{"issue":"10","key":"10.1016\/j.ejrad.2021.110107_b0040","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10105","key":"10.1016\/j.ejrad.2021.110107_b0045","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejrad.2021.110107_b0050","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejrad.2021.110107_b0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejrad.2021.110107_b0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: A Review in Advanced Melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejrad.2021.110107_b0065","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ejrad.2021.110107_b0070","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ejrad.2021.110107_b0075","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2021.110107_b0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2019.11.014","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics \u2013 Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"European J. Cancer"},{"key":"10.1016\/j.ejrad.2021.110107_b0085","doi-asserted-by":"crossref","unstructured":"E.C. Lin, Melanoma, in: A.A. Eugene C. Lin Third ed., PET and PET\/CT: A Clinical Guide, Thieme, New York, 2019, pp. 232-237.","DOI":"10.1055\/b-0039-166610"},{"issue":"1","key":"10.1016\/j.ejrad.2021.110107_b0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.suronc.2014.01.002","article-title":"Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis","volume":"23","author":"Rodriguez Rivera","year":"2014","journal-title":"Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2021.110107_b0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/jdv.12078","article-title":"Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study","volume":"28","author":"Jouvet","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1016\/j.ejrad.2021.110107_b0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11307-019-01413-7","article-title":"Whole-Body [(18)F]FDG-PET\/MRI vs","volume":"22","author":"Berzaczy","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ejrad.2021.110107_b0105","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1097\/RLU.0000000000001205","article-title":"Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET\/CT in Patients With Cutaneous Malignant Melanoma","volume":"41","author":"Son","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.ejrad.2021.110107_b0110","article-title":"Total lesion glycolysis by 18F-FDG PET\/CT is a reliable predictor of recurrence in cutaneous malignant melanoma","volume":"55","author":"Son","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ejrad.2021.110107_b0115","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"10.1016\/j.ejrad.2021.110107_b0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13550-018-0453-x","article-title":"Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET\/CT analysis","volume":"8","author":"de Heer","year":"2018","journal-title":"EJNMMI Res."},{"issue":"6","key":"10.1016\/j.ejrad.2021.110107_b0125","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2214\/AJR.18.19796","article-title":"Tumor Heterogeneity on FDG PET\/CT and Immunotherapy: An Imaging Biomarker for Predicting Treatment Response in Patients With Metastatic Melanoma","volume":"212","author":"Sanli","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2021.110107_b0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/CMR.0000000000000566","article-title":"Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma","volume":"29","author":"Boursi","year":"2019","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.ejrad.2021.110107_b0135","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","article-title":"Prognostic value of baseline metabolic tumor volume measured on (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy","volume":"46","author":"Ito","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"10.1016\/j.ejrad.2021.110107_b0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","article-title":"(18)F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma","volume":"20","author":"Wong","year":"2020","journal-title":"Cancer Imaging"},{"issue":"10","key":"10.1016\/j.ejrad.2021.110107_b0145","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1007\/s00259-012-2182-0","article-title":"Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma","volume":"39","author":"Bastiaannet","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.ejrad.2021.110107_b0150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.ejrad.2021.110107_b0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","article-title":"Predictive value of early 18 F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study","volume":"42","author":"Sachpekidis","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"23","key":"10.1016\/j.ejrad.2021.110107_b0160","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ejrad.2021.110107_b0165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","article-title":"The role of interim 18 F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma","volume":"45","author":"Sachpekidis","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"29","key":"10.1016\/j.ejrad.2021.110107_b0170","doi-asserted-by":"crossref","first-page":"e16417","DOI":"10.1097\/MD.0000000000016417","article-title":"Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET\/CT in patients with melanoma","volume":"98","author":"Amrane","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.1016\/j.ejrad.2021.110107_b0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-017-3813-2","article-title":"18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start","volume":"45","author":"Seith","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.ejrad.2021.110107_b0180","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.ejrad.2021.110107_b0185","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Annal. Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2021.110107_b0190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on 18 F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.ejrad.2021.110107_b0195","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-018-2183-3","article-title":"Longitudinal studies of the (18)F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET\/CT","volume":"67","author":"Sachpekidis","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejrad.2021.110107_b0200","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/curroncol28030152","article-title":"Early Reassessment of Total Metabolic Tumor Volume on FDG-PET\/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome","volume":"28","author":"Vermeulen","year":"2021","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.ejrad.2021.110107_b0205","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","article-title":"Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy","volume":"47","author":"Nakamoto","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2021.110107_b0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cancers13020168","article-title":"A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab","volume":"13","author":"Awada","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejrad.2021.110107_b0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"22","key":"10.1016\/j.ejrad.2021.110107_b0220","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejrad.2021.110107_b0225","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0959-8049(17)30482-3","article-title":"Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006","volume":"72","author":"Long","year":"2017","journal-title":"European J. Cancer"},{"key":"10.1016\/j.ejrad.2021.110107_b0230","doi-asserted-by":"crossref","first-page":"vi381","DOI":"10.1093\/annonc\/mdw379.08","article-title":"Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma","volume":"27","author":"Rai","year":"2016","journal-title":"Annal. Oncol."},{"issue":"31","key":"10.1016\/j.ejrad.2021.110107_b0235","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and Immune-Related Response in Solid Tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ejrad.2021.110107_b0240","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejrad.2021.110107_b0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.ejrad.2021.110107_b0250","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2021.110107_b0255","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2021.110107_b0260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejrad.2021.110107_b0265","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2021.110107_b0270","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/COC.0b013e318209cda9","article-title":"Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?","volume":"35","author":"Pennock","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ejrad.2021.110107_b0275","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X2100588X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X2100588X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:31:48Z","timestamp":1759995108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X2100588X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":55,"alternative-id":["S0720048X2100588X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2021.110107","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2021.110107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110107"}}